Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED (NYSE: CNMD) announced a leadership transition as CEO Curt R. Hartman will retire effective January 1, 2025. Current COO Patrick Beyer will succeed as President and CEO. During Hartman's 10-year tenure, CONMED nearly doubled revenues and more than doubled profitability through portfolio expansion and strategic acquisitions. Martha Goldberg Aronson will become Board Chair on October 31, 2024. Hartman will continue as a Director through December 2024 and remain as an advisor until March 2027. Beyer, who joined CONMED in 2014, has served in various leadership roles including President of International and Global Orthopedics, leading key acquisitions like In2Bones and BioRez.
CONMED (NYSE: CNMD) has released preliminary financial information for the third quarter of 2024. The company anticipates revenue between $315 million and $318 million, with adjusted diluted net earnings per share growth exceeding the previously guided 9% to 11%. CONMED will disclose full financial results on October 30, 2024, after market close, followed by a conference call at 4:30 p.m. ET.
The company emphasizes that this information is preliminary and subject to completion. While prepared in good faith and consistent with prior periods, actual results may differ materially as financial closing procedures for the period ended September 30, 2024, have not been completed. Investors are cautioned against relying heavily on this preliminary data.
CONMED (NYSE: CNMD) has announced its participation in a virtual fireside chat at the CL King 22nd Annual Best Ideas Conference. The event is scheduled for September 16, 2024, at 10:15 a.m. ET. Representing CONMED will be Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive Vice President and CFO.
Investors and interested parties can access a live video webcast of the fireside chat through the 'Investors' section of CONMED's official website at www.conmed.com. The webcast will also be available for replay after the event concludes, providing an opportunity for those unable to attend live to catch up on the discussion.
CONMED (NYSE: CNMD) has announced its participation in the Wells Fargo Healthcare Conference. Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will engage in a fireside chat on September 4, 2024, at 8:00 a.m. ET.
The event will be accessible via live webcast through the "Investors" section of CONMED's website at www.conmed.com. Interested parties can view the chat in real-time and access a replay after the event concludes. This participation provides an opportunity for investors and analysts to gain insights into CONMED's operations and strategies directly from its top executives.
CONMED (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The dividend was declared by the Board of Directors on August 8, 2024, and will be payable on October 4, 2024. Shareholders of record as of September 16, 2024, will be eligible to receive the dividend. This announcement demonstrates CONMED's commitment to returning value to its shareholders through regular dividend payments.
CONMED (NYSE: CNMD) reported its Q2 2024 financial results, showing sales of $332.1 million, a 4.5% year-over-year increase (5.2% in constant currency). Domestic revenue rose 6.1%, while international revenue grew 2.6% (4.0% in constant currency). The company's diluted net earnings per share (GAAP) reached $0.96, up from $0.43 in Q2 2023. Adjusted diluted net earnings per share increased by 18.1% to $0.98.
However, CONMED revised its 2024 outlook due to ongoing supply chain challenges. The company now expects full-year revenue between $1.305 billion and $1.315 billion, down from the previous range of $1.330-$1.355 billion. The adjusted diluted net earnings per share forecast was lowered to $3.95-$4.02, from the prior range of $4.25-$4.35.
CONMED (NYSE: CNMD) is set to release its financial results for the second quarter of 2024 on July 31, 2024, after the market close. A conference call to discuss these results will be hosted by the company's management at 4:30 p.m. ET on the same day. Investors can participate in the conference call by pre-registering to obtain the dial-in number and passcode. The call will also be webcast live on the 'Investors' section of CONMED's website, with a replay available approximately one hour after the call ends.
CONMED (NYSE: CNMD) announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 8:00 a.m. ET on June 6, 2024.
A live webcast will be accessible via the company's website and will be available for replay following the event.
CONMED (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The announcement was made on May 22, 2024, and the dividend will be payable on July 5, 2024. Shareholders of record as of June 14, 2024, will be eligible to receive this dividend. This decision reflects the company's ongoing commitment to returning value to its shareholders.
CONMED (NYSE: CNMD) will be presenting at the BofA Securities Healthcare Conference with top executives discussing the company's future on May 14, 2024. The event will be live-streamed on the company's website for investors to access.